Articles On Immutep (ASX:IMM)

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week “Another s...

Source:ShutterstockProfessional, Shutterstock Summary Lefroy Exploration has been making the headlines since the last month. The stock has shot up by over 63 per cent to A$1.125. Digital Wine Ventures has signed a memorandum of unders...

The best performer on the All Ordinaries index on Friday by some distance has been the Immutep Ltd (ASX: IMM) share price. In afternoon trade, the biotechnology company’s shares are up 29% to 44.5 cents. At one stage today, the Immutep sha...

Immutep (ASX:IMM) shares have spiked after Bristol Myers Squibb announced that a drug similar to Immutep’s lead candidate had succeeded in fighting cancer in a large study. Patients treated with Bristol Myer Squibb’s anti-LAG-3 monoclonal a...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Immutep (ASX:IMM) shares closed 10.5 per cent higher on Tuesday after the Sydney biotech announced it would collaborate with drug giant Merck & Co on another clinical trial. The two companies will hold a Phase IIb trial evaluating how t...

Source: CI Photos, Shutterstock Summary ASX-listed leading immunotherapy developer Immutep Limited entered into a second clinical trial collaboration with Merck & Co’s subsidiaries. Diagnostic company BARD1 Life Sciences revealed...

The Immutep Ltd (ASX: IMM) share price is soaring in early-afternoon trade. This comes after the company announced a second clinical trial collaboration with subsidiaries of Merck & Co. (MSD). At the time of writing, the biotechnology...

Immutep (ASX:IMM), an Australian biotechnology company developing novel immunotherapy treatments for cancer, infectious disease and autoimmune disease, has announced a second clinical trial collaboration and supply agreement with MS...

Immutep Ltd (ASX: IMM) shares will be on watch this morning after the company announced it has secured a second United States patent for eftilagimod alpha. The Immutep share price ended Tuesday’s trading session up 8.1% to 33 cents. Immute...

The Immutep Ltd (ASX: IMM) share price is down 1.59% at the time of writing trading at 31 cents a share. This follows this morning’s announcement that Immutep is expanding Part B of its cancer treatment clinical trial. Let’s break down wha...

Summary Respiri Limited announced that Pharmacy Catalyst members to provide support to sales of wheezo with the in-pharmacy asthma management program. The Company would continue to introduce the program across several other members pha...

When it comes to biotech stocks, few are as ambitious as Immutep Ltd [ASX:IMM]. Because when they’re not battling to try and treat cancer, they’re busy trying to stave off COVID-19. Which is exactly what has sent the IMM share price climbin...

Immutep (ASX:IMM) shares are up nearly five per cent this morning after the Sydney biotech said a trial of its ... Read More The post Immutep Covid-19 trial moves forward in Czech Republic appeared first on Stockhead.

Summary Global biotech company Immutep announces the advancement in Phase 2 trial assessing eftilagimod alpha in COVID-19 patients. The Company said that positive recommendation from the DSMB builds on strong safety profile for eftilag...

A trial of biotechnology company Immutep's (ASX: IMM) experimental cancer drug on COVID-19 patients will go ahead, after a preliminary test found the immune boosting drug was safe for use. As a result Immutep will see the trial progress t...

Summary Active biotechnology player Immutep has completed enrolment and dosing for the last patient in the TACTI-002 trial. The Company expects further data from the study in the first half of 2021. Immutep has also commenced the enro...

The Immutep Ltd (ASX: IMM) share price has failed to rally this morning after the company released an update on its cancer trial. The Sydney based biotechnology company’s share price lifted 1.23% to 41 cents in early morning trade, but has...

It has been a disappointing day for the S&P/ASX 200 Index (ASX: XJO) on Wednesday. In afternoon trade, the benchmark index is down 0.8% to 6,648.5 points. Four shares that have not let that hold them back today are listed below. Here’s...

In morning trade the Immutep Ltd (ASX: IMM) share price is storming higher following the release of an announcement. At the time of writing, the biotechnology company’s shares are up 9% to 42.5 cents. What did Immutep announce? This mornin...

Summary Immutep Ltd (ASX:IMM) received a US patent for its lead active immunotherapy candidate eftilagimod alpha along with a PD-1 pathway inhibitor. The United States Patent & Trade Mark Office has granted the patent number 10,874...

ShareCafeImmutep: fighting the good fight Immutep (ASX: IMM) are global leaders in the understanding and development of immunotherapy drugs for cancer and autoimmune diseases. IMM’s objective is to harness and strengthen the power of the bo...

The Immutep Ltd (ASX: IMM) share price is on watch this morning on news the company will significantly upscale its manufacturing capacity. The Immutep share price finished Wednesday’s trading session at 43 cents, up 6.1%. Immutep is a biot...

The Immutep Ltd (ASX: IMM) share price is on fire today, rising close to 60%. Immutep shares closed at 28 cents a share yesterday afternoon but opened at 45 cents this morning before rising to a high of 54 cents. The Immutep share price ha...

Immutep Limited (ASX: IMM) announced that its Chinese partner, EOC Pharma, will begin a new Phase II clinical trial on up to 152 metastatic breast cancer patients in China. Immutep Limited is a biotechnology company, which develops novel i...

Small-cap immunotherapy company Immutep Ltd [ASX:IMM] is absolutely flying today. The IMM share price is up 57.14% at time of writing. Spiking on some fantastic news the company had to share this morning.... The post Immutep Shares Soar 57%...

ShareCafeAustralia…One Hour In…ASX down 30 points ASX200 down 30 points (0.5%) to 6693.   UK PM Boris Johnson has been in Brussels trying to sort out Brexit and the news services are saying that “UK PM’s dinner with EU chief ends “with very...

Immunotherapy company Immutep (ASX:IMM) has announced what it describes as promising overall survival data from a breast cancer trial of its eftilagimod alpha and that its Chinese partner, EOC Pharma, will commence a new phase two c...

Global biotechnology company Immutep (ASX: IMM) has announced its Chinese partner EOC Pharma will commence a phase II clinical trial to evaluate the efficacy and safety of lead drug eftilagimod alpha in treating metastatic breast cancer. Th...

Summary Despite the challenges imposed by COVID-19, Volpara Heath delivered a substantial 38% revenue growth. Metrics such as gross margin and group ARPU also improved over the previous corresponding period. In 2H FY2021, Volpara would...

In afternoon trade the S&P/ASX 200 Index (ASX: XJO) is fighting back and is off its lows. The benchmark index is down 0.1% to 6,523.7 points currently. Four ASX shares that are falling more than most today are listed below. Here’s why...

19 Nov 2020 - Immutep Limited (ASX:IMM) is advancing clinical development for its lead product candidate eftilagimod alpha through the expansion of its ongoing TACTI-002 study and …

Immutep (ASX:IMM) has announced the completion of a $29.6 million share placement to professional, institutional and sophisticated investors, and an expanded collaboration with MSD.

The Immutep Ltd (ASX: IMM) share price went flying up this morning as the company announced encouraging results in its phase II trials. The company’s share price was trading up 5% at 31 cents in early trade. However, it has since retreated...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

Immutep (ASX:IMM) has announced a new licence and collaboration agreement with Laboratory Corporation of America Holdings that will support the development of immuno-oncology products or services.

Sydney biotech Immutep has partnered with S&P500 stock LabCorp to develop a diagnostic test helping doctors and oncologists. ... Read More The post Immutep partners with LabCorp to develop immotherapy diagnostic appeared first on Stockh...

Immutep (ASX:IMM) has signed an agreement with the University Hospital Pilsen in the Czech Republic that will enable an investigator-initiated randomised phase two clinical trial of its lead product candidate eftilagimod alpha (efti...

Sydney biotech Immutep (ASX:IMM) has agreed to let a Czech hospital test its lead drug candidate on dozens of COVID-19 ... Read More The post Czech hospital begins COVID study testing Immutep’s efti drug appeared first on Stockhead.

The Immutep Ltd (ASX: IMM) share price is heading lower today after the company announced its quarterly report for Q1 FY21. At the time of writing, the Immutep share price has dropped 3.85% to 25 cents. About Immutep Immutep is a biotechno...

Australian company Immutep (ASX:IMM), which is focused on the development of novel immunotherapy treatments for cancer and autoimmune disease, has been granted a new patent by the European Patent Office.

Shareholders in Antisense Therapeutics, Amplia Therapeutics and Immutep all had reason to smile this week A trio of capital raisings ... Read More The post ScoPo’s Health Powerplays: The money keeps flowing for the ASX biotechs appeared fir...

Summary Biotech player Immutep Limited reported interim data from its ongoing INSIGHT-004 Phase 1 clinical trial and Phase 2 TACTI-002 study. The interim findings from INSIGHT-004 trial demonstrate that the combination of eftilagimod al...

For many companies, making headway in a clinical trial is cause for celebration. But today, Immutep Ltd [ASX:IMM] has done it twice! That optimism has seen the IMM share price climb 23.26% higher at time of writing. A tidy return for a comp...

Three cancer patients’ lesions disappear after Immutep’s (ASX:IMM)treatment Treated with efti and Merck’s cancer-fighting drug Keytruda Two patients had aggressive ... Read More The post Immutep’s cancer-fighting drug candidate efti shows e...

The Immutep Ltd (ASX: IMM) share price is today flying as the company announced a number of results from its ongoing trials. The Immutep share price has gained a huge 20.45% today, rising to 26.5 cents at the time of writing. What Immutep...

Biotechnology company Immutep (ASX: IMM) has unveiled results from two parallel clinical studies into its lead drug eftilagimod alpha, citing “improving results” and “encouraging” early anti-tumour activity signals a variety of cancer indic...

Immutep (ASX:IMM) has announced it and research partner Monash University have received a grant under the ARC‘s Linkage Project scheme to support their research collaboration into LAG-3 for a further three years.